Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134141) titled 'A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Sintilimab Plus Ipilimumab N01 and Chemotherapy in Patients With Resectable cN1/N2 Driver Gene-Negative Non-Small Cell Lung Cancer' on Oct. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Soochow University
Condition:
Resectable cN1/N2 driver gene-negative non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-11
Target Sample Size: Experimental group:66;
Countries of Recruitment:
China
To know more, visit https://www.chi...